BioMarin has announced that it is pulling Roctavian, its gene therapy for adults with severe hemophilia A, from the market. The company reported that demand for the therapy remained far […]

Give 2 hours. Make a local impact. Hemophilia Ontario is proud to be a licensed charity partner at Superior Shores Gaming Centre (435 Memorial Avenue, Thunder Bay) and we’re looking […]

The Ontario Ministry of Health has announced that the Ontario Hepatitis C Assistance Plan (OHCAP) will be winding down after nearly 30 years of providing equitable access to hepatitis C […]

The Canadian Hemophilia Society has announced an important evolution: a new national name—Bleeding Disorders Canada. This change reflects the growth and diversity of the bleeding disorders community and aims to […]

The World Health Organization (WHO) Executive Board has endorsed a new resolution aimed at closing major gaps in care for people with hemophilia and other bleeding disorders. The resolution highlights […]

The Canadian Hemophilia Society (CHS) has formally asked the Provincial/Territorial Blood Liaison Committee to accept Canadian Blood Services’ recommendation to introduce Altuviiio (efanesoctocog alfa) for people with hemophilia A. Health […]

CSL Behring has signed a letter of intent with the pan‑Canadian Pharmaceutical Alliance to advance public reimbursement discussions for Hemgenix, the first gene therapy approved for hemophilia B. The agreement […]

Canadian Blood Services is pushing to strengthen Canada’s self‑reliance in plasma‑derived medicines. Demand for immunoglobulins continues to rise, yet most of Canada’s supply still comes from the United States. CBS […]